ReviewEndocrine2006
Central nervous system biogenic amine targets for control of appetite and energy expenditure.
Review in Endocrine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- A novel microbiome metabolic modulator improves the growth performance of broiler chickens in multiple trials and modulates targeted energy and amino acid metabolic pathways in the cecal metagenome.Poultry science · 2021Pooled it
- Central noradrenaline transporter availability in highly obese, non-depressed individuals.European journal of nuclear medicine and molecular imaging · 2017Trial
- Effects of psychostimulants on locomotor activity in the BTBR TPsychopharmacology · 2026Article
- Exploring the Impact of Extended Amino Acid Supplementation on Body Composition and Psychopathology in Patients with Eating Disorders Undergoing Psycho-Nutritional RehabilitationEndocrine, metabolic & immune disorders drug targets · 2026Article
- Increasing dietary indigestible protein may exacerbate coccidiosis in broiler chickens.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Article
- Lower incidence of diabetic retinopathy and worsening events after phentermine assisted weight loss across a large U.S. cohort.Eye (London, England) · 2025Article
- Pharmacotherapy for Obesity: Recent Updates.Clinical pharmacology : advances and applications · 2025Review
- Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.Alpha psychiatry · 2024Review
- Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?Current obesity reports · 2024Review
- Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review.Cell & bioscience · 2023Review
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.EClinicalMedicine · 2023Review
- Increased adipose catecholamine levels and protection from obesity with loss of Allograft Inflammatory Factor-1.Nature communications · 2023Article
- Chronic abdominal vagus stimulation increased brain metabolic connectivity, reduced striatal dopamine transporter and increased mid-brain serotonin transporter in obese miniature pigs.Journal of translational medicine · 2019Article
- Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?Journal of endocrinological investigation · 2018Article
- Phentermine induces conditioned rewarding effects via activation of the PI3K/Akt signaling pathway in the nucleus accumbens.Psychopharmacology · 2016Article
- Weight management in obesity - past and present.International journal of clinical practice · 2016Review
- High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes.Genes & nutrition · 2014Article
- Interleukin 13 and serotonin: linking the immune and endocrine systems in murine models of intestinal inflammation.PloS one · 2013Article
- The use of serotonergic drugs to treat obesity--is there any hope?Drug design, development and therapy · 2011Review
- The use of lorcaserin in the management of obesity: a critical appraisal.Drug design, development and therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central biogenic amine systems have long been studied for their effects on feeding behavior, energy balance, and maintenance of body weight. Those monoaminergic systems that use dopamine (DA), norepinephrine (NE), and serotonin (5-hydroxytryptamine, 5-HT) as neurotransmitters have been the main targets of study. A number of antiobesity medications that affect monoaminergic activity have appeared on the market and/or in clinical trials. Early examples of such agents are the so-called CNS stimulants, e.g., the amphetamines, phentermine, ephedrine, etc. These agents release monoamines from neuronal stores, and their antiobesity activity seems to be tied most closely to their ability to release NE. Inhibitors of neuronal reuptake of NE or 5-HT have been shown to reduce feeding and weight gain both preclinically and clinically. However, the magnitude and sustainability of such effects in clinical trials has generally not been great enough to register or label these agents for the treatment of obesity. Sibutramine, however, is an exception. This compound is metabolized in vivo to produce metabolites that have varying degrees of inhibition of NE, 5-HT, and/or DA uptake. Sibutramine is the only drug affecting monoaminergic systems currently approved for the long-term control of obesity. Research continues on serotonergic and histaminergic systems to determine if targets such as the 5-HT2C and H3 receptors may be suitable for developing antiobesity agents. Because the clinical antiobesity effects of monoaminergic drugs have been modest, future directions include looking at combinations of different monoaminergic mechanisms and/or combinations of monoaminergic drugs with non-monoaminergic mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.